首页> 外文期刊>European archives of psychiatry and clinical neuroscience >Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.
【24h】

Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.

机译:奥氮平与喹硫平对精神分裂症急性发作患者认知功能障碍的疗效。

获取原文
获取原文并翻译 | 示例
           

摘要

Neurocognitive impairment is a core feature in the pathology of schizophrenia and considered to be relatively persistent towards psychopharmacological interventions. There are hints that atypical antipsychotics can influence neurocognitive dysfunctions more favorable than conventional compounds. But little is known about differences in efficacy on neurocognitive dysfunctions linked to the variety of receptor profiles of different atypical antipsychotics. This study compared the effects of the atypical antipsychotics quetiapine and olanzapine on cognitive function in patients with an acute episode of schizophrenia. Patients were randomized to receive quetiapine or olanzapine for 8 weeks. Cognitive function was assessed at baseline, week 4 and week 8. Efficacy was assessed weekly using the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Improvement Scale (CGI). Tolerability was assessed each week using the Extrapyramidal Symptom Rating Scale (ESRS), the Barnes Akathisia Scale (BAS) and the Udvalg for Kliniske Undersogelser Side Effect Rating Scale (UKU). In total, 52 patients were enrolled in the study. Data from the 33 patients who completed cognitive assessments at two or more time points out of three (baseline, Week 4 and Week 8) are analyzed here. Both quetiapine and olanzapine improved global cognitive index z-scores, however, this was more marked with quetiapine. Between-group comparisons showed significantly greater improvements in reaction quality/attention with quetiapine than olanzapine. Quetiapine and olanzapine produced significant improvements from baseline to week 8 in PANSS total and subscale scores. Both treatments were well tolerated, especially no EPS occurred during 8 weeks of treatment. Both quetiapine and olanzapine improved cognition; however, the improvement in cognitive index scores was more marked in patients receiving quetiapine. Furthermore, quetiapine produced a significantly greater improvement in reaction quality/attention than olanzapine.
机译:神经认知障碍是精神分裂症病理学的核心特征,被认为在心理药物干预中相对持久。有迹象表明,非典型抗精神病药比传统化合物对神经认知功能障碍的影响更大。但是,关于与不同非典型抗精神病药的各种受体特征相关的神经认知功能障碍的功效差异知之甚少。这项研究比较了非典型抗精神病药物喹硫平和奥氮平对精神分裂症急性发作患者认知功能的影响。患者随机接受喹硫平或奥氮平治疗8周。在基线,第4周和第8周评估认知功能。每周使用阳性和阴性综合征量表(PANSS)和临床总体改善量表(CGI)评估疗效。每周使用锥体外系症状评定量表(ESRS),Barnes Akathisia量表(BAS)和Kliniske Undersogelser副作用评定量表(UKU)评估Udvalg的耐受性。总共有52名患者参加了该研究。在这里分析了33名患者的数据,这些患者在三个或三个以上的时间点(基线,第4周和第8周)中完成了认知评估。喹硫平和奥氮平均改善了整体认知指数z评分,但喹硫平更显着。组间比较显示,喹硫平比奥氮平的反应质量/注意力显着提高。从基线到第8周,喹硫平和奥氮平的PANSS总分和分量表得分均有显着改善。两种治疗均耐受良好,尤其是在治疗8周内未发生EPS。喹硫平和奥氮平均可提高认知度;然而,接受喹硫平的患者认知指数得分的改善更为明显。此外,与奥氮平相比,喹硫平在反应质量/注意力上的改善显着更大。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号